Free tool
FAERS Monitor: Vyvgart Hytrulo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761304 or its brand name (Vyvgart Hytrulo, Efgartigimod Alfa and Hyaluronidase-Qvfc). Reports on generic versions are filed under their own applications.
Reports
485
Serious
426
88% of reports
Hospitalization
170
Death reported
23
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- myasthenia gravis68
- fatigue67
- asthenia40
- drug ineffective38
- fall37
- muscular weakness37
- injection site erythema25
- myasthenia gravis crisis25
- condition aggravated24
- headache24
- injection site pain24
- therapy change23
- chronic inflammatory demyelinating polyradiculoneuropathy22
- dyspnoea21
- urinary tract infection21
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 1 |
| 2022 | 2 |
| 2023 | 23 |
| 2024 | 198 |
| 2025 | 132 |
| 2026 | 129 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,674 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| myasthenia gravis crisisSignal | 25 | 744.3 | 506.4 | 17,523 |
| chronic inflammatory demyelinating polyradiculoneuropathySignal | 22 | 674.4 | 446.9 | 13,913 |
| myasthenia gravisSignal | 68 | 368.2 | 295.1 | 24,339 |
| therapy changeSignal | 23 | 101.7 | 68.2 | 2,189 |
| muscular weaknessSignal | 37 | 14.1 | 10.4 | 440 |
| injection site erythemaSignal | 25 | 8.7 | 6.0 | 165 |
| urinary tract infectionSignal | 21 | 5.3 | 3.5 | 70 |
| fallSignal | 37 | 4.8 | 3.5 | 110 |
| astheniaSignal | 40 | 4.6 | 3.4 | 112 |
| fatigueSignal | 67 | 3.7 | 3.0 | 136 |
| condition aggravatedSignal | 24 | 3.4 | 2.3 | 39 |
| injection site painSignal | 24 | 3.4 | 2.3 | 39 |
| headache | 24 | 1.7 | 1.1 | 6 |
| dyspnoea | 21 | 1.6 | 1.1 | 4 |
| drug ineffective | 38 | 1.3 | 0.9 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.